Voriconazole and posaconazole therapy for experimental Candida lusitaniae infection
Abstract The in vitro activity of posaconazole (PSC) and voriconazole (VRC) was tested by using time-kill studies against 3 strains of Candida lusitaniae . Both drugs showed fungistatic activity against all strains. The efficacy of those compounds was evaluated by reducing kidney fungal burden and b...
Gespeichert in:
| Veröffentlicht in: | Diagnostic microbiology and infectious disease 2016, Vol.84 (1), p.48-51 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 51 |
|---|---|
| container_issue | 1 |
| container_start_page | 48 |
| container_title | Diagnostic microbiology and infectious disease |
| container_volume | 84 |
| creator | Sanchis, Marta Guarro, Josep Sutton, Deanna A Fothergill, Annette W Wiederhold, Nathan Capilla, Javier |
| description | Abstract The in vitro activity of posaconazole (PSC) and voriconazole (VRC) was tested by using time-kill studies against 3 strains of Candida lusitaniae . Both drugs showed fungistatic activity against all strains. The efficacy of those compounds was evaluated by reducing kidney fungal burden and by determining (1→3)-β- d -glucan serum levels in a murine model of invasive infection of C. lusitaniae . The therapies tested were VRC at 10, 25, or 40 mg/kg/day and PSC at 5, 12.5, or 20 mg/kg/twice a day. All the dosages showed efficacy in a dose-dependant manner being high doses of both antifungals able to sterilize some kidneys after 10 days. With the exception of the strain FMR 9474, against which PSC was more effective than VRC, no differences in reducing tissue burden were found between the treatments. All doses of both antifungals were able to significantly reduce (1→3)-β- d -glucan serum levels with no significant differences between treatments and between the same doses of both drugs. |
| doi_str_mv | 10.1016/j.diagmicrobio.2015.09.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1762355021</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0732889315003442</els_id><sourcerecordid>1762355021</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-42995194207ffeb27ca2da08e37d4220fb4e3229e05d689386172b4286f630413</originalsourceid><addsrcrecordid>eNqNkU2r1TAQhoMo3uPVvyDFlZvWyUeTxoUgx0-44OKq25CmU82xJ6lJKx5_vSnnehFXrgaGZ2Z4nyHkCYWGApXPDs3g7Zejdyn2PjYMaNuAboDCHbKjndI1gIK7ZAeKs7rrNL8gD3I-AFCmBdwnF0yKVvJO7cj155i8i8H-ihNWNgzVHLO9bSxfMdn5VI0xVfhzxuSPGBY7VfuC-sFW05r9YoO3WPkwolt8DA_JvdFOGR_d1Evy6c3rj_t39dWHt-_3L69qJ2S31IJp3VItGKhxxJ4pZ9lgoUOuBsEYjL1AzphGaAdZQnSSKtYL1slRchCUX5Kn571zit9XzIs5-uxwmmzAuGZDlWS8bYFt6PMzWpzlnHA0c4li08lQMJtUczB_SzWbVAPaFKll-PHNnbU_4nA7-sdiAV6dASxpf3hMJjuPweHgU1Fihuj_786Lf9a4yQfv7PQNT5gPcU2h-DTUZGbAXG_v3b5LWwAuBOO_AQfWpBo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1762355021</pqid></control><display><type>article</type><title>Voriconazole and posaconazole therapy for experimental Candida lusitaniae infection</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Sanchis, Marta ; Guarro, Josep ; Sutton, Deanna A ; Fothergill, Annette W ; Wiederhold, Nathan ; Capilla, Javier</creator><creatorcontrib>Sanchis, Marta ; Guarro, Josep ; Sutton, Deanna A ; Fothergill, Annette W ; Wiederhold, Nathan ; Capilla, Javier</creatorcontrib><description>Abstract The in vitro activity of posaconazole (PSC) and voriconazole (VRC) was tested by using time-kill studies against 3 strains of Candida lusitaniae . Both drugs showed fungistatic activity against all strains. The efficacy of those compounds was evaluated by reducing kidney fungal burden and by determining (1→3)-β- d -glucan serum levels in a murine model of invasive infection of C. lusitaniae . The therapies tested were VRC at 10, 25, or 40 mg/kg/day and PSC at 5, 12.5, or 20 mg/kg/twice a day. All the dosages showed efficacy in a dose-dependant manner being high doses of both antifungals able to sterilize some kidneys after 10 days. With the exception of the strain FMR 9474, against which PSC was more effective than VRC, no differences in reducing tissue burden were found between the treatments. All doses of both antifungals were able to significantly reduce (1→3)-β- d -glucan serum levels with no significant differences between treatments and between the same doses of both drugs.</description><identifier>ISSN: 0732-8893</identifier><identifier>EISSN: 1879-0070</identifier><identifier>DOI: 10.1016/j.diagmicrobio.2015.09.010</identifier><identifier>PMID: 26456387</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animal model ; Animals ; Antifungal ; Antifungal Agents - administration & dosage ; beta-Glucans - blood ; Candida - drug effects ; Candida lusitaniae ; Candidiasis - drug therapy ; Colony Count, Microbial ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Fungal infections ; Humans ; Infectious Disease ; Internal Medicine ; Kidney - microbiology ; Male ; Mice ; Posaconazole ; Treatment Outcome ; Triazoles - administration & dosage ; Voriconazole ; Voriconazole - administration & dosage</subject><ispartof>Diagnostic microbiology and infectious disease, 2016, Vol.84 (1), p.48-51</ispartof><rights>Elsevier Inc.</rights><rights>2016 Elsevier Inc.</rights><rights>Copyright © 2016 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-42995194207ffeb27ca2da08e37d4220fb4e3229e05d689386172b4286f630413</citedby><cites>FETCH-LOGICAL-c468t-42995194207ffeb27ca2da08e37d4220fb4e3229e05d689386172b4286f630413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0732889315003442$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,4009,27902,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26456387$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sanchis, Marta</creatorcontrib><creatorcontrib>Guarro, Josep</creatorcontrib><creatorcontrib>Sutton, Deanna A</creatorcontrib><creatorcontrib>Fothergill, Annette W</creatorcontrib><creatorcontrib>Wiederhold, Nathan</creatorcontrib><creatorcontrib>Capilla, Javier</creatorcontrib><title>Voriconazole and posaconazole therapy for experimental Candida lusitaniae infection</title><title>Diagnostic microbiology and infectious disease</title><addtitle>Diagn Microbiol Infect Dis</addtitle><description>Abstract The in vitro activity of posaconazole (PSC) and voriconazole (VRC) was tested by using time-kill studies against 3 strains of Candida lusitaniae . Both drugs showed fungistatic activity against all strains. The efficacy of those compounds was evaluated by reducing kidney fungal burden and by determining (1→3)-β- d -glucan serum levels in a murine model of invasive infection of C. lusitaniae . The therapies tested were VRC at 10, 25, or 40 mg/kg/day and PSC at 5, 12.5, or 20 mg/kg/twice a day. All the dosages showed efficacy in a dose-dependant manner being high doses of both antifungals able to sterilize some kidneys after 10 days. With the exception of the strain FMR 9474, against which PSC was more effective than VRC, no differences in reducing tissue burden were found between the treatments. All doses of both antifungals were able to significantly reduce (1→3)-β- d -glucan serum levels with no significant differences between treatments and between the same doses of both drugs.</description><subject>Animal model</subject><subject>Animals</subject><subject>Antifungal</subject><subject>Antifungal Agents - administration & dosage</subject><subject>beta-Glucans - blood</subject><subject>Candida - drug effects</subject><subject>Candida lusitaniae</subject><subject>Candidiasis - drug therapy</subject><subject>Colony Count, Microbial</subject><subject>Disease Models, Animal</subject><subject>Dose-Response Relationship, Drug</subject><subject>Fungal infections</subject><subject>Humans</subject><subject>Infectious Disease</subject><subject>Internal Medicine</subject><subject>Kidney - microbiology</subject><subject>Male</subject><subject>Mice</subject><subject>Posaconazole</subject><subject>Treatment Outcome</subject><subject>Triazoles - administration & dosage</subject><subject>Voriconazole</subject><subject>Voriconazole - administration & dosage</subject><issn>0732-8893</issn><issn>1879-0070</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU2r1TAQhoMo3uPVvyDFlZvWyUeTxoUgx0-44OKq25CmU82xJ6lJKx5_vSnnehFXrgaGZ2Z4nyHkCYWGApXPDs3g7Zejdyn2PjYMaNuAboDCHbKjndI1gIK7ZAeKs7rrNL8gD3I-AFCmBdwnF0yKVvJO7cj155i8i8H-ihNWNgzVHLO9bSxfMdn5VI0xVfhzxuSPGBY7VfuC-sFW05r9YoO3WPkwolt8DA_JvdFOGR_d1Evy6c3rj_t39dWHt-_3L69qJ2S31IJp3VItGKhxxJ4pZ9lgoUOuBsEYjL1AzphGaAdZQnSSKtYL1slRchCUX5Kn571zit9XzIs5-uxwmmzAuGZDlWS8bYFt6PMzWpzlnHA0c4li08lQMJtUczB_SzWbVAPaFKll-PHNnbU_4nA7-sdiAV6dASxpf3hMJjuPweHgU1Fihuj_786Lf9a4yQfv7PQNT5gPcU2h-DTUZGbAXG_v3b5LWwAuBOO_AQfWpBo</recordid><startdate>2016</startdate><enddate>2016</enddate><creator>Sanchis, Marta</creator><creator>Guarro, Josep</creator><creator>Sutton, Deanna A</creator><creator>Fothergill, Annette W</creator><creator>Wiederhold, Nathan</creator><creator>Capilla, Javier</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>M7N</scope></search><sort><creationdate>2016</creationdate><title>Voriconazole and posaconazole therapy for experimental Candida lusitaniae infection</title><author>Sanchis, Marta ; Guarro, Josep ; Sutton, Deanna A ; Fothergill, Annette W ; Wiederhold, Nathan ; Capilla, Javier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-42995194207ffeb27ca2da08e37d4220fb4e3229e05d689386172b4286f630413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animal model</topic><topic>Animals</topic><topic>Antifungal</topic><topic>Antifungal Agents - administration & dosage</topic><topic>beta-Glucans - blood</topic><topic>Candida - drug effects</topic><topic>Candida lusitaniae</topic><topic>Candidiasis - drug therapy</topic><topic>Colony Count, Microbial</topic><topic>Disease Models, Animal</topic><topic>Dose-Response Relationship, Drug</topic><topic>Fungal infections</topic><topic>Humans</topic><topic>Infectious Disease</topic><topic>Internal Medicine</topic><topic>Kidney - microbiology</topic><topic>Male</topic><topic>Mice</topic><topic>Posaconazole</topic><topic>Treatment Outcome</topic><topic>Triazoles - administration & dosage</topic><topic>Voriconazole</topic><topic>Voriconazole - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sanchis, Marta</creatorcontrib><creatorcontrib>Guarro, Josep</creatorcontrib><creatorcontrib>Sutton, Deanna A</creatorcontrib><creatorcontrib>Fothergill, Annette W</creatorcontrib><creatorcontrib>Wiederhold, Nathan</creatorcontrib><creatorcontrib>Capilla, Javier</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><jtitle>Diagnostic microbiology and infectious disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sanchis, Marta</au><au>Guarro, Josep</au><au>Sutton, Deanna A</au><au>Fothergill, Annette W</au><au>Wiederhold, Nathan</au><au>Capilla, Javier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Voriconazole and posaconazole therapy for experimental Candida lusitaniae infection</atitle><jtitle>Diagnostic microbiology and infectious disease</jtitle><addtitle>Diagn Microbiol Infect Dis</addtitle><date>2016</date><risdate>2016</risdate><volume>84</volume><issue>1</issue><spage>48</spage><epage>51</epage><pages>48-51</pages><issn>0732-8893</issn><eissn>1879-0070</eissn><abstract>Abstract The in vitro activity of posaconazole (PSC) and voriconazole (VRC) was tested by using time-kill studies against 3 strains of Candida lusitaniae . Both drugs showed fungistatic activity against all strains. The efficacy of those compounds was evaluated by reducing kidney fungal burden and by determining (1→3)-β- d -glucan serum levels in a murine model of invasive infection of C. lusitaniae . The therapies tested were VRC at 10, 25, or 40 mg/kg/day and PSC at 5, 12.5, or 20 mg/kg/twice a day. All the dosages showed efficacy in a dose-dependant manner being high doses of both antifungals able to sterilize some kidneys after 10 days. With the exception of the strain FMR 9474, against which PSC was more effective than VRC, no differences in reducing tissue burden were found between the treatments. All doses of both antifungals were able to significantly reduce (1→3)-β- d -glucan serum levels with no significant differences between treatments and between the same doses of both drugs.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26456387</pmid><doi>10.1016/j.diagmicrobio.2015.09.010</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-8893 |
| ispartof | Diagnostic microbiology and infectious disease, 2016, Vol.84 (1), p.48-51 |
| issn | 0732-8893 1879-0070 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1762355021 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animal model Animals Antifungal Antifungal Agents - administration & dosage beta-Glucans - blood Candida - drug effects Candida lusitaniae Candidiasis - drug therapy Colony Count, Microbial Disease Models, Animal Dose-Response Relationship, Drug Fungal infections Humans Infectious Disease Internal Medicine Kidney - microbiology Male Mice Posaconazole Treatment Outcome Triazoles - administration & dosage Voriconazole Voriconazole - administration & dosage |
| title | Voriconazole and posaconazole therapy for experimental Candida lusitaniae infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T23%3A05%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Voriconazole%20and%20posaconazole%20therapy%20for%20experimental%20Candida%20lusitaniae%20infection&rft.jtitle=Diagnostic%20microbiology%20and%20infectious%20disease&rft.au=Sanchis,%20Marta&rft.date=2016&rft.volume=84&rft.issue=1&rft.spage=48&rft.epage=51&rft.pages=48-51&rft.issn=0732-8893&rft.eissn=1879-0070&rft_id=info:doi/10.1016/j.diagmicrobio.2015.09.010&rft_dat=%3Cproquest_cross%3E1762355021%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1762355021&rft_id=info:pmid/26456387&rft_els_id=S0732889315003442&rfr_iscdi=true |